Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Pembrolizumab and IO102-103 Prior to Curative-intent Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT05977907 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor.

NCT NCT05977907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05977907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Pembrolizumab and IO102-103 Prior to Curative-intent Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 14, 2023
Completion date
October 16, 2028
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma